Author: Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Title: Network-based Drug Repurposing for Human Coronavirus Document date: 2020_2_5
ID: b4mdiont_53
Snippet: Integration of drug-target networks, HCoV-host interactions, HCoV-induced transcriptome in human cell lines, and human protein-protein interactome network are essential for such identification. Based on comprehensive evaluation, we prioritized 16 putative repurposable drugs ( Figure 5 ) and 3 putative drug combinations (Figure 6 ) for the potential treatment of HCoVs, including 2019-nCoV. However, all network-predicted repurposable drugs and drug.....
Document: Integration of drug-target networks, HCoV-host interactions, HCoV-induced transcriptome in human cell lines, and human protein-protein interactome network are essential for such identification. Based on comprehensive evaluation, we prioritized 16 putative repurposable drugs ( Figure 5 ) and 3 putative drug combinations (Figure 6 ) for the potential treatment of HCoVs, including 2019-nCoV. However, all network-predicted repurposable drugs and drug combinations must be validated in preclinical models and randomized clinical trials before being used in patients.
Search related documents:
Co phrase search for related documents- cell line and comprehensive evaluation: 1
- cell line and drug combination: 1, 2, 3, 4
- cell line and drug target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- cell line and drug target network: 1, 2
- cell line and hcov host: 1, 2
- cell line and HCoV induced transcriptome: 1
- cell line and human cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83
- cell line and human protein protein: 1, 2, 3, 4, 5
- cell line and network predict: 1
- cell line and potential treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- cell line and preclinical model: 1, 2
- cell line and protein protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical trial and comprehensive evaluation: 1, 2, 3
- clinical trial and drug combination: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- clinical trial and drug target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- clinical trial and hcov host: 1
- clinical trial and human cell line: 1, 2
- clinical trial and human protein protein: 1
- clinical trial and potential treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
Co phrase search for related documents, hyperlinks ordered by date